Skip to content
Subscriber Only

Teva Fourth-Quarter Profit Rises 23% on Cephalon Acquisition

Teva Pharmaceutical Industries Ltd. said fourth-quarter profit rose 23 percent as last year’s acquisition of Cephalon Inc. shifted the company further away from its original identity as a generic-drug maker.

Earnings excluding some costs climbed to $1.4 billion, or $1.59 a share, from $1.1 billion, or $1.25, a year earlier, the Petach Tikva, Israel-based company said in a statement today. Profit matched the average estimate of $1.59 a share from 25 analysts surveyed by Bloomberg.